MedTrace Logo

ALF-ONE : ALFuzosin ONcE Daily

NCT00280605 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2010-08-31

No results posted yet for this study

Summary

The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).

Conditions

  • Prostatic Hyperplasia

Interventions

DRUG

Alfuzosin

Sponsors & Collaborators

Principal Investigators

  • Benedict Blayney, MD · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-02-28
Completion
2006-02-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00280605 on ClinicalTrials.gov